Clinical trial

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

NCT02985658

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Veliparib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Vinorelbine Normalized identity: vinorelbineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Design: EXPANDED_ACCESS · Status: NO LONGER AVAILABLE · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Conditions

Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutationunresolved

Triple-Negative Breast Cancerverified · MONDO: triple-negative breast carcinoma

Interventions

VeliparibDRUG

CisplatinDRUG · verified · RxNorm: cisplatin

VinorelbineDRUG · verified · RxNorm: vinorelbine

Sponsors & collaborators

University of Washingtonlead sponsor

AbbViecollaborator

Mapped research locations

SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02985658 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.